Treatment of opioid withdrawal

A technology for opioid drug withdrawal, which is applied in the field of treatment and/or prevention of opioid drug withdrawal, and can solve problems such as side effects

Pending Publication Date: 2022-05-13
KINOXIS THERAPEUTICS PTY LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, in clinical trials, lofexidine treatment resulted in only modest improvements in acute opioid withdrawal symptoms and treatment retention, while also causing associated side effects, including hypotension, bradycardia, and insomnia
Also, lofexidine is only approved for use up to 14 days

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Treatment of opioid withdrawal
  • Treatment of opioid withdrawal
  • Treatment of opioid withdrawal

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0227] The preparation method of the compound of formula (I) is as described in PCT / AU2016 / 050588.

[0228] Method of administration

[0229] As defined herein, a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof may be administered by any suitable means, for example, orally, rectally, nasally, vaginally, topically (including buccal and lingual) ), parenterally, eg, by subcutaneous, intraperitoneal, intravenous, intramuscular, or intracerebral injection, inhalation, insufflation, infusion, or implantation techniques (eg, as sterile injectable aqueous or non-aqueous solutions or suspensions).

[0230] The compounds of the present invention may be provided as pharmaceutical compositions, including oral, rectal, nasal, topical (including buccal and sublingual), parenteral (including intramuscular, intraperitoneal, subcutaneous and intravenous), or in a form suitable for administration by inhalation Or administered in the form of insufflation. Comp...

Embodiment 1

[0285] This example describes experiments in a C57BL / 6 mouse opioid withdrawal model (naloxone-facilitated withdrawal following oxycodone administration) and the potential of compounds of the invention to treat withdrawal symptoms.

[0286]

[0287]

[0288] drug

[0289] All drugs used in this study were dissolved in physiological saline and administered in a volume of 10 ml / kg.

[0290] Experiment 1.1: The effect of CMPD1-2HCL on field exercise ability

[0291] The purpose of this experiment was to demonstrate that CMPD1-2HCL does not cause potentially confounding effects on locomotor activity at doses of 5 and 10 mg / kg. N=18 adult male C57BL / 6 mice received 0, 5 or 10 mg / kg CMPD1-2HCL (i.p.; n=6 per group). Fifteen minutes after receiving intraperitoneal injection of CMPD1-2HCL, the mice were individually placed in a new 40(l)x 40(w)x 40(h)cm locomotor testing field. The testing session was captured by an overhead camera and the video was analyzed using the automat...

Embodiment 2

[0327] In this example, the ability of compound 1 to inhibit c-fos protein expression induced by naloxone-induced opioid withdrawal in the brain was investigated. C-fos is a protein marker of neural activation. Compound 1 was administered as the dihydrochloride salt (CMPD1-2HCL).

[0328] method

[0329] N=40 male C57BL / 6 mice were divided into the following four groups:

[0330] (1) VEH, VEH (n = 10)

[0331] (2) VEH, CMPD1-2HCl (n = 10)

[0332] (3) OXY, VEH (n = 10)

[0333] (4) OXY, CMPD1-2HCl (n = 10)

[0334] Mice in the oxycodone (OXY) group received intraperitoneal injections of oxycodone for 9 days with increasing doses of 9, 17.8, 23.7 and 33 mg / kg (twice a day on days 1-8, with dose increases every other day). The morning and afternoon doses are separated by 7 hours. Vehicle group (VEH) mice received injections of vehicle saline instead of oxycodone. One hour and 45 minutes after the morning injection on day 9, mice were intraperitoneally injected with CMPD1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to methods of treating, preventing, managing and / or controlling opioid withdrawal and / or symptoms associated with opioid withdrawal. The invention provides compounds, compositions, medicaments and kits useful in these methods.

Description

[0001] Cross References to Related Applications [0002] This application claims priority to Australian Provisional Patent Application No. 2019903299, filed 6 September 2019, the entirety of which is incorporated herein by reference. technical field [0003] The present invention relates to methods of treating and / or preventing opioid withdrawal. [0004] Background of the invention [0005] Opioids and opiates are a useful class of analgesics that are widely used for pain relief. Opioids and opiates have also become drugs of abuse -- both as recreational users and as patients developing opioid use disorder after treatment with opioids. Stopping opioids and / or opiates may also lead to opioid withdrawal. Opioid withdrawal is a physiological condition resulting from a subject's physical dependence on opioids and / or opiates, which may, in some cases, occur after short-term exposure to opioids and / or opiates This situation. [0006] For example, iatrogenic opioid withdrawal s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5513A61K31/485A61P25/36C07D487/04C07D498/04C07D513/04
CPCA61K31/485A61K2300/00A61K31/5513C07D498/04C07D513/04A61P25/36C07D487/04A61K31/5517A61K45/06
Inventor M·T·博文I·S·麦格雷戈
Owner KINOXIS THERAPEUTICS PTY LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap